SHP2 inhibition diminishes KRAS(G12C) cycling and promotes tumor microenvironment remodeling

KRAS is the most frequently mutated human oncogene, and KRAS inhibition has been a longtime goal. Recently, inhibitors were developed that bind KRAS(G12C)-GDP and react with Cys-12 (G12C-Is). Using new affinity reagents to monitor KRAS(G12C) activation and inhibitor engagement, we found that an SHP2...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Med
Main Authors: Fedele, Carmine, Li, Shuai, Teng, Kai Wen, Foster, Connor J.R., Peng, David, Ran, Hao, Mita, Paolo, Geer, Mitchell J., Hattori, Takamitsu, Koide, Akiko, Wang, Yubao, Tang, Kwan Ho, Leinwand, Joshua, Wang, Wei, Diskin, Brian, Deng, Jiehui, Chen, Ting, Dolgalev, Igor, Ozerdem, Ugur, Miller, George, Koide, Shohei, Wong, Kwok-Kin, Neel, Benjamin G.
Formato: Artigo
Idioma:Inglês
Publicado em: Rockefeller University Press 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7549316/
https://ncbi.nlm.nih.gov/pubmed/33045063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20201414
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados